Profile: Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

3.03USD
26 Dec 2014
Price Change (% chg)

$-0.05 (-1.62%)
Prev Close
$3.08
Open
$3.08
Day's High
$3.14
Day's Low
$2.99
Volume
472,709
Avg. Vol
893,361
52-wk High
$6.70
52-wk Low
$2.45

Search Stocks

Synergy Pharmaceuticals, Inc., incorporated on February 11, 1992, is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company’s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company’s active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors.

As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor. As of December 31, 2011, the Company was dosing patients in an 800-patient Phase II/III clinical trial of plecanatide to treat. It is also developing a second generation GC-C receptor analog, SP-333, which is in pre-clinical development for the treatment of gastrointestinal inflammatory diseases. SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone.

The Company competes with Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., Takeda Pharmaceuticals America, Inc., Sucampo Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc. and Shire Plc.

Company Address

Synergy Pharmaceuticals Inc

SUITE 2012, 420 LEXINGTON AVENUE
NEW YORK   NY   10170
P: +1212.2970010
F: +1212.2970019

Company Web Links

Search Stocks